Condition: Solid Tumor · Hematological Malignancy · Sponsor: Institut Bergonié
This is a biology driven, monocentric study designed to identify actionable molecular alterations in cancer patients with advanced disease. In this trial, high throughput analysis will be carried out using next generation sequencing, and immunological profiling. Patients included in the BIP study and for whom a targetable genomic alteration had been identified might be subsequently included in an early phase trials running at Institut Bergonie or another French hospital.
This description comes directly from the study's public registry record.
Antoine ITALIANO, MD, PhD · a.italiano@bordeaux.unicancer.fr
Simone MATHOULIN-PELISSIER, MD, PhD · s.mathoulin@bordeaux.unicancer.fr
Always discuss trial participation with your own doctor first.
| Centre Hospitalier de la Côte Basque | Bayonne, France | Recruiting |
| Clinique Tivoli-Ducos | Bordeaux, France | Recruiting |
| Institut Bergonie | Bordeaux, France | Recruiting |
| Polyclinique Bordeaux Nord Aquitaine | Bordeaux, France | Recruiting |
| Centre Hospitalier de Pau | Pau, France | Not Yet Recruiting |
| Clinique Marzet | Pau, France | Recruiting |
| Centre Eugène Marquis | Rennes, France | Active Not Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02534649